COMPOSITIONS AND METHODS FOR TREATING EPILEPSY AND RELATED DISORDERS
The present disclosure is in the field of pharmaceutical compositions suitable for the treatment of diseases in mammals. The disclosure provides novel compositions comprising non-pathogenic fecal microbes for treating epilepsy, epileptic seizures and related diseases. The disclosure also provides methods for treating a subject with the compositions disclosed herein.
1 . A method for treating epilepsy or seizure in a subject in need thereof, said method comprising orally administering to said subject a pharmaceutically active dose of a therapeutic composition comprising uncultured fecal bacteria.
2 . The method of claim 1 , wherein said seizure is selected from the group consisting of focal or generalized seizures.
3 . The method of claim 2 , wherein said focal seizure is selected from the group consisting of simple focal seizure, complex focal seizure, and secondary generalized seizure.
4 . The method of claim 2 , wherein said generalized seizure is selected from the group consisting of absence, tonic, atonic, clonic, myoclonic, or tonic-clonic seizures.
5 . The method of claim 1 , wherein said method reduces the overall frequency of seizures.
6 . The method of claim 1 , wherein said methods prevent a relapse in seizures.
7 . The method of claim 5 , wherein said method reduces said frequency by at least 10%, 20%, 30%, 50%, 60%, 70%, 80%, or 90% after 4, 8, or 12 weeks of treatment.
8 . The method of claim 1 , wherein said administration is on a daily or weekly basis.
9 . The method of claim 1 , wherein said composition is in a capsule.
10 . The method of claim 1 , wherein said composition is in a liquid, frozen, freeze-dried, spray-dried, foam-dried, lyophilized, or powder form.
11 . The method of claim 1 , wherein said capsule is an enteric coated capsule, an acid-resistant, enteric-coated capsule, or an enteric coated microcapsule.
12 . The method of claim 1 , wherein said subject is pretreated with an antibiotic prior to administration of said composition.
13 . The method of claim 1 , wherein said administration comprises an induction treatment and a maintenance treatment.
14 . The method of claim 13 , wherein said induction period comprises administering a greater number of capsules per day than said maintenance treatment.
15 . The method of claim 1 , wherein said subject in need thereof is deficient in one or more of Akkermansia or Parabacteroides species relative to a subject who does not have epilepsy.
16 . The method of claim 1 , wherein said subject in need thereof is non-responsive to ketogenic diet (KD) therapy.
17 . A method of treating epilepsy or seizure in a subject in need thereof, said method comprising determining the relative abundance of one or more Akkermansia or Parabacteroides species in an intestine of the subject and orally administering to said subject a pharmaceutically active dose of a therapeutic composition comprising a non-selected fecal microbiota if the relative abundance of the one or more Akkermansia or Parabacteroides species is less than a threshold level.
18 . A method of treating epilepsy or seizure in a subject in need thereof, said method comprising administering to said subject a pharmaceutically active dose of a therapeutic composition comprising uncultured fecal bacteria, wherein said subject is free of gut dysbiosis immediately prior to said treating.
19 . The method of claim 18 , wherein said composition is in a capsule.
20 . The method of claim 18 , wherein said composition is in a liquid, frozen, freeze-dried, spray-dried, foam-dried, lyophilized, or powder form.